Accelerating Biologics Development
simultaneously optimize affinity, developability, and safety with
in vivo
B cell display
Our Platform
How does it work?
Primary B cells engineered to express biologic
Engineered B cells engrafted into mice
Mice immunized with drug target
Engineered cells affinity mature in germinal centers
Improved clones isolated and characterized
Why does it work?
Innovative editing method promotes somatic hypermutation
Genuine mammalian post-translational modifications
Affinity maturation efficiently explores sequence space
Selects against sequences with poor
in vivo
behavior
Read more:
Pan et al.,
In vivo affinity maturation of the CD4 domains of an HIV-1 entry inhibitor
,
Nat Biomed Eng
2024
Yin et al.,
In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies
,
Nat Biomed Eng
2024
He et al.,
Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates
,
Immunity
2023
Ou et al.,
Reprogramming of the heavy-chain CDR3 regions of a human antibody repertoire
,
Mol Ther
2022
Our Team
Mai Tran
PhD
Tianling Ou
PhD
Andi Pan
PhD
Charles Bailey
DVM
Mike Farzan
PhD
Contact Us
inquiries@nuwagen.bio
Platform
Team
Contact